Anji Pharma Overview
- Year Founded
-
2018
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
Anji Pharma General Information
Description
Developer of metabolic drugs designed to provide a medical treatment for chronic diseases. The company's drugs help cure chronic diseases, pain, cardiovascular and cerebrovascular diseases, and also serve other unmet medical needs, enabling patients to cure health conditions effectively.
Contact Information
Website
anjipharma.comCorporate Office
- Cambridge Innovation Center
- Kendall Square, 245 Main Street
- Cambridge, MA 02142
- United States
Corporate Office
- Cambridge Innovation Center
- Kendall Square, 245 Main Street
- Cambridge, MA 02142
- United States
Anji Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Out of Business | 05-Jun-2025 | Completed | Out of Business | |||
| 5. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 4. Early Stage VC (Series B) | 28-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A1) | 16-Sep-2020 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 28-Jun-2019 | $14M | $23M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC | 13-Jul-2018 | $9M | $9M | Completed | Pre-Clinical Trials |
Anji Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Anji Pharma Patents
Anji Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240141029-A1 | Methods and compositions for treating sepsis | Inactive | 05-Mar-2021 | ||
| WO-2022187353-A1 | Methods and compositions for treating sepsis | Inactive | 05-Mar-2021 | ||
| AU-2019282132-A1 | Compositions and methods for treating pancreatitis | Inactive | 05-Jun-2018 | ||
| AU-2019282132-A8 | Compositions and methods for treating pancreatitis | Inactive | 05-Jun-2018 | ||
| CA-3102032-A1 | Compositions and methods for treating pancreatitis | Pending | 05-Jun-2018 | A61K38/4813 |
Anji Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Anji Pharma Investments (1)
Anji Pharma’s most recent deal was a Corporate Asset Purchase with Broad Institute of MIT (MCL1 Inhibitor Program). The deal was made on 10-Jun-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Broad Institute of MIT (MCL1 Inhibitor Program) | 10-Jun-2021 | Corporate Asset Purchase | Buildings and Property |
Anji Pharma FAQs
-
When was Anji Pharma founded?
Anji Pharma was founded in 2018.
-
Where is Anji Pharma headquartered?
Anji Pharma is headquartered in Cambridge, MA.
-
What is the size of Anji Pharma?
Anji Pharma has 3 total employees.
-
What industry is Anji Pharma in?
Anji Pharma’s primary industry is Drug Discovery.
-
Is Anji Pharma a private or public company?
Anji Pharma is a Private company.
-
What is Anji Pharma’s current revenue?
The current revenue for Anji Pharma is .
-
How much funding has Anji Pharma raised over time?
Anji Pharma has raised $105M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
